Purpose: We designed a phase I-II trial of three active agents, paclitaxel, ifosfamide, and vinorelbine, in advanced non-smallcell lung cancer (NSCLC) to: 1) define the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of paclitaxel with filgrastim (G-CSF) support; and 2) determine the overall response rate and median survival of patients treated on this regimen.
Introduction
Despite recent advances in diagnosis and therapy, nonsmall-cell lung cancer remains the most common cause of cancer death [1] . Based on a documented prolongation of survival compared to supportive care alone [2] , chemotherapy has become the standard of care for patients with metastatic disease. Phase III trials have shown a survival advantage for new combinations such as cisplatin-vinorelbine [3] , or cisplatin-paclitaxel [4] , over previous 'standard' regimens.
Despite improvements in supportive care, cisplatinrelated toxicities remain prohibitive, and further investigation of non-cisplatin-based chemotherapy regimens remains of interest. We developed this three-drug regimen based on the encouraging single-agent activity of each of these drugs and pre-clinical evidence of a vinorelbine-paclitaxel synergy [5] , as well as the favorable therapeutic index for the two-drug regimens ifosfamidepaclitaxel [6] and ifosfamide-vinorelbine [7] in separate University of Chicago phase I trials.
Patients and methods

Study design
This was a conventional phase I cohort dose escalation trial, followed by a full phase II evaluation of the regimen. We employed the daily x 3 vinorelbine schedule used in our previously reported two-drug regimen of ifosfamide and vinorelbine [7] . The primary goals of the phase I portion of the study were to define the maximum tolerated dose (MTD) of paclitaxel in this three-drug regimen and to describe the doselimiting toxicities (DLT). Primary objectives during the phase II portion were to determine the overall (complete and partial) response rates and the median and one-year survival of patients treated on this study.
Methods
This study accrued patients at three institutions from January 1995 to November 1996. Eligibility criteria included a CALGB performance status 0-2, histologically or cytologically proven NSCLC staged 1MB or IV, and measurable or evaluable disease. Prior treatment with a single experimental chemotherapy agent was allowed, provided it did not include any of the drugs in this combination regimen. All patients enrolled in the phase II portion of the trial were required to have measurable disease. Adequate hematologic, renal, and hepatic func- 2 (4) 26 (46) 30 (54) 16 (29) 13 (23) 5 (9) 27 (48) 11 (20) 18 (32) tion were required, as was witnessed, signed informed consent from all patients. Patients completing one full cycle of therapy or experiencing DLT were considered evaluable for toxicity. All patients completing two full cycles were evaluable for response, and all patients registered were followed for survival.
Treatment schema
Ifosfamide was given on an in-patient basis on days 1-3 with mesna. Vinorelbine was given following ifosfamide on days 1-3, a schedule previously reported by these authors [7] . Pachtaxel was given as a onehour infusion on day 2 following vinorelbine. The paclitaxel dose was escalated in cohorts of patients. Patients received intravenous ondansetron or granisetron as an anti-emetic and were pretreated with dexamethasone. G-CSF was administered to all patients at 5 mcg/kg/day starting on day 5 and continuing until the post-nadir absolute neutrophil count was ^ 10,000/mcl. Cycles were repeated every 21 days.
Dose escalation
In the phase I portion of the trial, we planned to treat three to six patients per dose level. Paclitaxel dose levels included 100 mg/m 2 . 135 mg/m 2 , 150 mg/m 2 , and 175 mg/m 2 . If two of three or three of six patients at a given dose experienced DLT, the previous dose was declared the MTD and recommended phase II dose (RPTD). Intrapatient dose escalation did not occur. Additional patients were treated at the RPTD (for a total of 35 patients) to further evaluate the efficacy and toxicities of this regimen.
Dose-limiting toxicity was defined during cycle 1 as grade IV hematologic toxicity lasting greater than four days or neutropenic fever (absolute neutrophil count < 1000/mcl and fever > 38.3 C). Nonhematologic DLT was defined as grade III toxicity lasting beyond seven days or the inability to receive therapy on c>cle 2 due to ongoing grade II or greater toxicity. Recommended phase 11 dose.
Results
Fifty-six patients were enrolled on this study (Table 1) . Twenty-seven patients were treated on the phase I portion of the study, with an additional 29 patients added to the phase II dose for a total of 35 patients at the RPTD. Twelve patients had received prior investigational singleagent chemotherapy including eight with prior 9-aminocamptothecin, three docetaxel, and one JM-216. Median follow-up is greater than 18 months, with all patients followed for at least nine months.
Toxicity
The 56 patients enrolled were treated on five different dose levels (Table 2) . One patient was not evaluable for toxicity or response after it was determined he was ineligible due to elevated liver function studies. Due to DLT on dose level 1 of ifosfamide 1.6 g/m 2 x 3, vinorelbine 25 mg/m 2 x 3 and paclitaxel 100 mg/m 2 , the ifosfamide and vinorelbine doses were reduced by 25% and 20%, respectively, for all subsequent levels. When paclitaxel escalation was attempted beyond 135 mg/m 2 unacceptable toxicity occurred with dose-limiting neutropenia in three of five patients at 175 mg/m 2 and four of six patients at 150 mg/m 2 . Thus the recommended phase II dose in this trial was paclitaxel 135 mg/m 2 with ifosfamide 1.2 g/m 2 /day on days 1-3 and vinorelbine to 20 mg/m 2 /day on days 1-3 with G-CSF support. On the phase I portion of the trial, grade III-IV nonhematologic toxicities observed included pulmonary toxicity (unexplained pneumonitis) in five patients, fatigue in two patients, cardiac arrhythmias (supraventricular tachycardias) in two patients, confusion in one patient, and peripheral neuropathy in one patient. One patient had grade III nausea and vomiting, with no patient suffering grade III-IV mucositis, constipation, or creatinine rise. Of 35 patients treated at the RPTD, toxicities included 22 patients (63%) with grade IV neutropenia and eight (23%) with neutropenic fever (Table 3) . Other grade III-IV toxicities included one pulmonary, one diarrhea, two fatigue, and one severe non-neutropenic infection (pneumonia). No grade III-IV nausea, vomiting, anorexia, mucositis, constipation, or renal, cardiac, or neurological toxicities were observed at the RPTD. 
a Eight of these patients had febrile neutropenia. This table displays the toxicity observed in the phase II portion of the study, while data reported in the 'Results' section comprise both phase I and II patients. Abbreviations' ANC -absolute neutrophil count; PNS -peripheral nervous system neuropathy; CNS -central nervous system toxicity.
Although prior research demonstrated a synnergistic effect when vinorelbine was given before paclitaxel, in vitro models have now shown antagonism when paclitaxel is given before vinorelbine [8] . Both of these drugs act on the microtubule, therefore sequencing may be critical. Since taxoids stabilize microtubules, the cytotoxic effects of vinorelbine (inhibition of microtubule formation during mitosis) may be diminished following paclitaxel. Administration of paclitaxel following the completion of vinorelbine might avoid this antagonism to produce a more active regimen.
Further research also needs to determine if threedrug regimens using the new chemotherapy agents are more active than two-drug combinations in general. Several randomized trials have shown that two-drug combinations are superior to single agents [3, 9] . At our institution we are now investigating the role of threedrug regimens with a phase I-II study of paclitaxel, ifosfamide and carboplatin with G-CSF in advanced NSCLC [10] . These and other trials will help define the optimal regimens for the treatment of advanced NSCLC.
Response
Of 55 evaluable patients, no complete and 10 partial responses produced an overall response rate of 18%. Six of 35 patients (17%, 95% CI: 7%-34%) treated at the phase II dose achieved a partial response. Using the Kaplan-Meier method of estimating the survivor curve, median survival for all patients was 6.1 months, with a one-year survival of 34% (95% CI: 22%-46%).
Five of 13 patients (38%) with prior chemotherapy exposure responded to this regimen, compared to five of 42 previously untreated patients (12%). Of note, responses were observed at nearly all dose levels of therapy. This trial has demonstrated that the combination of paclitaxel, ifosfamide, and vinorelbine can be given with growth factor support in patients with advanced nonsmall-cell lung cancer. The response rate of 18% and median survival of 6.1 months however, are disappointing, especially considering our experience with ifosfamide and vinorelbine at the University of Chicago which produced a 40% response rate and a 50-week median survival [7] . It is unclear if the lower response rate in this trial relates to inadequate dosing, some antagonistic drug interaction, or other factors.
The MTD in this study included doses of vinorelbine and paclitaxel below those commonly used to treat advanced non-small-cell lung cancer. These doses may be below the minimum effective dose for each agent. A true threshold dose for these drugs has not been determined, but is likely to exceed doses used here.
An antagonistic effect of the drugs or sequence used in this three-drug regimen may have occurred as well.
